Rezac Rebecca L
From UCHealth Blood Disorders and Cell Therapies Center, Aurora, Colorado.
J Adv Pract Oncol. 2024 Apr;15(3):177-181. doi: 10.6004/jadpro.2024.15.3.4. Epub 2024 Apr 1.
At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring and management of side effects of new therapies for hematologic malignancies.
在奥兰多举行的2023年JADPRO直播活动中，药学博士、肿瘤化疗药剂师丽贝卡·L·雷扎克总结了2022年末至2023年末美国食品药品监督管理局批准的关键信息。雷扎克博士介绍了血液系统恶性肿瘤新疗法的适应症、作用机制以及副作用的监测和管理。
